EGFR and cancer: Another bispecific antibody (hEGFRvIII-CD3) comprising two scFv fragments (one specific to the EGFRvIII antigen and another to the CD3 epitope) was designed to create a bridge between EGFR-expressing cancer cells and CD3+ T cells, and to prevent a non-specific targeting to EGFR-negative cells.